The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | Treatment strategies for cHL patients after auto-HSCT
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses different treatment strategies for patients with classical Hodgkin lymphoma (cHL) that relapse or progress after autologous-hematopoietic stem cell transplant (auto-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
